Clinical Laboratory Improvement Advisory Committee (CLIAC)
CLIAC is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services (HHS); the Assistant Secretary for Health; the Director of the CDC; the Commissioner of the FDA; and the Administrator of CMS. The Committee’s guidance focuses on improvement in clinical laboratory quality and laboratory medicine practice and specific issues on any revision of the Clinical Laboratory Improvement Amendment (CLIA) standards, including impact on medical and laboratory practice; and modification of standards and non-regulatory guidelines to accommodate technological advances, such as new test methods or electronic transmission of laboratory information.
The Committee includes diverse membership across laboratory specialties, professional roles, (laboratory management, technical, physicians, nurses) and practice settings (academic, clinical, public health), and includes a consumer representative. The laboratory specialties represented include microbiology, immunology, chemistry, hematology, immunohematology, cytopathology, histopathology, genetic testing, and informatics. The Committee also includes three ex officio members from the federal agencies that oversee the CLIA program: the CDC, CMS, and the FDA. In addition, a nonvoting liaison representing the laboratory industry participates on the Committee.